Inside Haematologica: new concepts in the management of multiple myeloma.
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002448:Cell Adhesion; D002465:Cell Movement; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D003131:Combined Modality Therapy; D000075202:Contraindications; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D019656:Loss of Heterozygosity; D008558:Melphalan / Q000494:pharmacology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D010950:Plasma Cells / Q000473:pathology; D019030:Receptors, Vitronectin / Q000502:physiology; D015398:Signal Transduction; D033581:Stem Cell Transplantation; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology
D018906:Antineoplastic Agents, Alkylating; D019030:Receptors, Vitronectin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan